House: Delay OHSA's ergonomics standard Supplement labels

Labeling is of "infinitely greater regulatory urgency" than the safety criterion in setting regulatory priorities and resource allocation because the vast majority of policy issues involve product claims. GMA does not believe additional labeling regulations are needed. GMA thinks FDA should focus on ensuring that claims on dietary supplements are truthful and not misleading, as well as enforcing the rules against misbranding. GMA also believes FDA should replace its proposed structure/function regulations with a guidance that retains the 1993 definition of disease and excludes indirect implied disease claims from the drug category.